Clinica Study Of Radio-frequeney Hyperthermia Ablation With Concurrent Chemoradiotherapy In Treatment Of Tumors Of Lung

Objective: To investigate the efficacy and safety of percutaneous electrode radio-frequeney hyperthermia ablation guided by computerized tomography (CT) for the treatment of middle-late stage non-small cell lung cancer (NSCLC) and lung metastases.Methods: 96 patients of non-small cell lung cancer (NSCLC)and lung metastases with different pathology types were treated by radiorequency technique in 2009 July to January 2011. The 96 cases were randomly divided into 2 groups. One group of 49 patients was treated with comprehensive therapy of radiofrequeney ablation, radiotherapy and chemotherapy (RFA group). The other one of 47 patients was treated with radiotherapy combined with chemotherapy (radio- and chemo-therapy group). The RFA group is on the basis of chemotherapy added the CT-guided percutaneous radiofrequency ablation, while the radio- and chemo-therapy group only used radiotherapy and chemotherapy. The patient's blood pressure, pulse rate and oxygen saturation were monitored during the procedure; the liver, pulmonary, renal functions and pain symptoms were examined before and after the procedure.Observe postoperative harmful complications. The changes of tumor bulk and low-density shadow (LDS) were checked with CT 3 months after the treatment. The 1 year survival rate, recurrence rate, KPS score and adverse reaction of radiotherapy and chemotherapy were concluded.Results: In the RFA group, there were no changes in the blood pressure,pulse rate and oxygen saturation in the whole series before and after treatment, no obvious adverse complications (pneumothorax, hemothorax, coughing up blood and pulmonary infection), nor were the pulmonary functions either.In RFA group : at the end of the third month after therapy , the CT scanning of the tumor revealed that there were 8 complete regression (CR),constituted 16.33% of 49 patients ; 35 partial regression (PRa), took up 71.42 % of the 49 patients; 5 slight partial regression (PRb),took up 10.20 % of the 49 patients; and 1 no regression(NR: the decrease of tumor bulk was less than 50%), took up 2.04 % of the 49 patients. In the radio- and chemo-therapy group: at the end of the third month after therapy ,3 complete regression (CR),constituted 6.38% of 47 patients ; 15 partial regression (PRa), took up 31.91 % of the 47 patients; 23 slight partial regression (PRb),took up 48.94 % of the 47 patients; and 6 no regression, took up 12.76 % of the 47 patients. By the end of the third month after therapy , the LDS of 49 patients of RFA group were checked by CT , the results showed: I type 2 patients, 4.08 % ;Ⅱtype 12 patients , 24.49 % ;Ⅲtype 35 patients , 71.76 % . In the radio- and chemo-therapy group, there are 9 I type , 19.14%; 27Ⅱtype, 57.45% ; and 11Ⅲtype, 23.40% . The 12 months survival rates of RFA group and the radio- and chemo-therapy group were 91.84% and 80.85%. The recurrence rates of RFA group and chemo-therapy group were 4.08% and 17.02%.Conclusion: Excellent clinical effects and safety of treatment for middle-late stage non-small cell lung cancer (NSCLC) and lung metastases with electrode radiofrequeney hyperthermia ablation placed percutaneously by CT guided were recognized, it can significantly improve the patients tumor size, tumor density shadow; obviously improve patients' quality of life, effectively reduce pain symptoms, can significantly raise patients'1 year survival rate,prevent tumor recurrence. As the comprehensive therapy of radiofrequeney ablation, radiotherapy and chemotherapy is safe and aesy to operate, it has the well foreground was prognosticated.